Promises
3 promises
Promise Tracker
0 delivered, 0 close, 3 missed.
View Promises →
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Dr. Reddy's Q1 FY26 results showed 11% YoY revenue growth to INR 8,545 crore, driven by steady performance across most markets except US generics. EBITDA margin of 26.7% declined 149 bps YoY due to price erosion in lenalidomide and higher SG&A from NRT and nutraceutical investments. PAT grew 2% YoY to INR 1,419 crore. Management expects lenalidomide sales to drop sharply after Q2, with semaglutide launch in Canada targeted for early 2026 pending approval and IP clearance. The company aims to maintain 25%+ EBITDA margins through cost optimization, but near-term headwinds from generic pricing and elevated SG&A persist. Risk: Lenalidomide revenue decline could pressure margins more than anticipated if new launches underperform.
डॉ. रेड्डीज़ की पहली तिमाही (अप्रैल-जून 2025) के नतीजे: - कुल कमाई 8,545 करोड़ रुपये, जो पिछले साल से 11% ज़्यादा है। - मुनाफ़ा (EBITDA) 26.7% रहा, जो पिछले साल से थोड़ा कम है। इसकी वजह है लेनालिडोमाइड दवा की कीमतों में गिरावट और नए उत्पादों (NRT, न्यूट्रास्युटिकल) पर ज़्यादा खर्च। - शुद्ध मुनाफ़ा (PAT) 1,419 करोड़ रुपये, पिछले साल से 2% ज़्यादा। - कंपनी को उम्मीद है कि लेनालिडोमाइड की बिक्री दूसरी तिमाही के बाद तेज़ी से घटेगी। सेमाग्लूटाइड दवा कनाडा में 2026 की शुरुआत में लॉन्च हो सकती है (मंज़ूरी मिलने पर)। - कंपनी 25% से ज़्यादा मुनाफ़ा बनाए रखने की कोशिश करेगी, लेकिन जेनेरिक दवाओं की कीमतों में गिरावट और बढ़ते खर्च से चुनौती है। - जोखिम: अगर नई दवाएँ उम्मीद के मुताबिक नहीं चलीं, तो लेनालिडोमाइड की कम बिक्री से मुनाफ़ा और गिर सकता है।
Promises0 met · 3 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Lenalidomide revenue decline sharper than expected
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
North America Revenue
$400M
-17% YoY
Decline driven by price erosion in lenalidomide and timing of customer procurement.
Europe Generics Revenue
EUR 131M
+124% YoY
Growth fueled by NRT acquisition and new product launches.
India Business Revenue
INR 1,471 Cr
+11% YoY
Double-digit growth from new products and pricing; outpaced IPM.
Semaglutide Capacity (FY27)
12M pens
N/A
Capacity from partner for FY27; internal capacity from FY28 onward.
What Changed vs Last Quarter
NEW
R&D spend 7%-7.5% of sales for FY26
R&D investments expected in this range for the full fiscal year.
NEW
CapEx outflow INR 2,500-2,700 crore for FY26
Capital expenditure for the full year expected in this range, primarily for peptides and biosimilars.
NEW
EBITDA margin aspiration of 25%+ for base business
Aims to maintain EBITDA margin north of 25% for the base business, with semaglutide expected to be accretive.
UPDATED
Semaglutide launch in Canada by early 2026
Expects approval between end-Oct and early-Nov 2025, with launch at LOE in Jan 2026, subject to IP clearance and approval.
DROPPED
Double-digit revenue growth in FY26
Management expects double-digit revenue growth for FY2026, including contributions from new launches and biosimilars, despite REVLIMID exclusivity ending in January 2026.
DROPPED
EBITDA margin maintained at ~28% in FY26
Management guided for EBITDA margins to remain around 28% in FY2026, similar to FY2025 levels, through productivity measures and revenue growth.
DROPPED
Abatacept filing by end of CY2025
Phase III trials ongoing; submission planned for end of 2025, with IV launch expected immediately after patent expiry and sub-Q launch a year later.
NEW RISK
Lenalidomide revenue decline sharper than expected
Lenalidomide sales expected to drop significantly after Q2 FY26; magnitude depends on pricing and competitor behavior.
NEW RISK
Semaglutide launch delays due to IP or regulatory hurdles
Canadian launch contingent on patent litigation outcome in India and FDA approval; any delay could push revenue to later quarters.
NEW RISK
US generic price erosion persists
Base US business faces ongoing price erosion; management expects flat to single-digit growth but uncertainty remains.
NEW RISK
SG&A costs may remain elevated
SG&A at 30% of sales in Q1; management targets 28-29% for full year, but NRT and nutraceutical investments could keep it higher.
RISK GONE
U.S. tariffs on generics
Potential tariffs on pharmaceutical imports could impact margins; management is working with customers to ensure supply continuity but uncertainty remains.
RISK GONE
REVLIMID revenue cliff in January 2026
Exclusivity ends in January 2026, leading to significant revenue decline; management expects to offset through growth in other segments but risk remains.
RISK GONE
Gross margin volatility from one-off costs
Q4 gross margin fell 300 bps due to manufacturing overhead and lower milestone income; while management considers it one-off, recurrence could pressure margins.
RISK GONE
Semaglutide competition in Canada
Multiple players may launch generic semaglutide in Canada, leading to price erosion and lower-than-expected market share for Dr. Reddy's.
🤫 Topics management stopped discussing
Mentioned in Q2 FY25, Q4 FY25
Exclusivity ends in January 2026, leading to significant revenue decline; management expects to offset through growth in other segments but risk remains.
Fast read
Guidance and risk preview
Expects approval between end-Oct and early-Nov 2025, with launch at LOE in Jan 2026, subject to IP clearance and approval.
Lenalidomide sales expected to drop significantly after Q2 FY26; magnitude depends on pricing and competitor behavior.
View Risks →